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Background: TNF-related apoptosis inducing ligand (TRAIL) belongs to the TNF-superfamily that induces apoptotic
cell death in a wide range of neoplastic cells in vivo as well as in vitro. We identified two alternative TRAIL-splice
variants, i.e. TRAIL-β and TRAIL-γ that are characterized by the loss of their proapoptotic properties. Herein, we
investigated the expression and the prognostic values of the TRAIL-splice variants in gastric carcinomas.
Methods: Real time PCR for amplification of the TRAIL-splice variants was performed in tumour tissue specimens
and corresponding normal tissues of 41 consecutive patients with gastric carcinoma. Differences on mRNA-expression
levels of the TRAIL-isoforms were compared to histo-pathological variables and correlated with survival data.
Results: All three TRAIL-splice variants could be detected in both non-malignant and malignant tissues, irrespective of
their histological staging, grading or tumour types. However, TRAIL-β exhibited a higher expression in normal gastric
tissue. The proapoptotic TRAIL-α expression was increased in gastric carcinomas when compared to TRAIL-β and TRAIL-γ.
In addition, overexpression of TRAIL-γ was associated with a significant higher survival rate.
Conclusions: This is the first study that investigated the expression of TRAIL-splice variants in gastric carcinoma tissue
samples. Thus, we provide first data that indicate a prognostic value for TRAIL-γ overexpression in this tumour entity.
Keywords: TRAIL, Alternative splicing, Apoptosis, Gastric carcinomaBackground
TRAIL/APO2L (tumour necrosis factor related apoptosis-
inducing ligand) is classified accordingly to its membran-
ous topology as type II transmembrane protein that was
identified by two research groups as a member of the TNF
superfamily [1,2]. Unlike other TNF family members, such
as TNFα or CD95L/FasL, TRAIL was detected in numer-
ous normal as well as malignant cells and tissues [1,2]. In
addition, it has been shown that TRAIL triggered apop-
totic cell death in cancer cells, while most normal cells
remained unaffected [3-7]. Interestingly, treatment of
tumour cells with recombinant TRAIL suppressed their* Correspondence: andreas.krieg@med.uni-duesseldorf.de; mahotka@uni-
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reproduction in any medium, provided the orgrowth in mice [8] and improved survival of tumour-
bearing animals [3]. Thus, making the TRAIL-system a
promising target for anticancer therapies, that are still
under investigation in several clinical trials as reviewed by
Dimberg and colleagues [9].
The identification of five receptors that are capable to
bind TRAIL suggests that signal transduction mediated by
TRAIL is more complex when compared to the signaling
pathways of other TNF-family members [7,10-16].
Upon binding of TRAIL to the death domain con-
taining receptors TRAIL-R1/DR4 and TRAIL-R2/DR5/
KILLER/TRICK2, receptor homotrimerization is in-
duced, leading to the formation of a so called death in-
ducing signaling complex (DISC) which sets the
apoptotic machinery in motion [5,6,15-21]. However,
TRAIL-R3/DcR1/TRID, lacking a cytoplasmic domain
and TRAIL-R4/DcR2/TRUNDD, exhibiting an incom-
plete death domain, protect cells from TRAIL-inducedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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though with a low affinity, osteoprotegerin (OPG) has
also been reported to bind TRAIL [12].
In addition to the apoptosis inducing signaling cas-
cade, TRAIL can also activate pathways that promote
survival and cell proliferation via the NF-кB, protein kin-
ase B/Akt and MAP-Kinase pathways [10,23-27]. Thus,
cells that are characterized by a death resistant pheno-
type when treated with TRAIL may convert into highly
aggressive tumours that exhibit an increase in prolifera-
tion and metastatic capacity when stimulated with
TRAIL [28,29]. Thereby, mechanisms promoting TRAIL
resistance have been identified on different levels of the
TRAIL pathway. These mechanisms include i.e. muta-
tions of death receptors, overexpression of FLICE-like
inhibitory protein, Bcl2 family proteins or Inhibitor of
apoptosis (IAP) proteins [9].
Recently, several studies have focused on the prognos-
tic significance of the TRAIL-system in different types of
cancer. Interestingly, TRAIL-positive tumours less fre-
quently obtained a pathological complete response in
cervical cancer [30]. Poorly differentiated areas in
NSCLC showed a strong staining pattern for TRAIL
[31] and in colorectal cancer an increased TRAIL ex-
pression within the tumour was associated with worse
overall survival [32].
Alternative splicing is a posttranscriptional modifica-
tion process that has been shown to be involved in the
regulation of apoptosis by promoting the translation of
multiple proteins from a single gene that results in a
sometimes functionally heterogenic pool of proteins with
antagonistic functions [33,34].
Recently, we were able to identify and characterize also
alternative splice variants of genes that belong to the
TRAIL-system [35,36]. Alternative splicing of the TRAIL
pre-mRNA led to the synthesis of two isoforms that
were designated TRAIL-β and TRAIL-γ [35]. Both
TRAIL-β and TRAIL-γ exhibited structurally an exten-
sive truncation of their N-terminal binding domain
which functionally was associated with the inability of
mediating any proapoptotic signal.
Although previously the expression levels of TRAIL
were investigated in gastric carcinomas [37], to date
there are no data available that analyzed the expression
of the alternative TRAIL splice variants in malignant dis-
eases such as gastric carcinomas (for better discrimin-
ation TRAIL is denoted in this article as TRAIL-α).
Thus, in our study we focused now on the quantification
of mRNA levels of TRAIL-α TRAIL-β and TRAIL-γ in
gastric carcinomas and correlated these expression levels
with clinico-pathological variables and survival data.
Since there are currently no specific antibodies available
that can distinguish between the different splice vari-
ants, we quantified their expression levels by performinga reverse transcriptase and polymerase chain reaction
(RT–PCR).
Using this experimental approach our data suggest
that alternative splicing of the TRAIL gene might be in-
volved in the molecular pathology of gastric carcinomas.
Methods
Patients and specimens
Matched neoplastic and non-neoplastic tissue specimens
were obtained from 41 consecutive patients who under-
went subtotal or total gastrectomy because of gastric
carcinomas between 1996 and 2000.
After surgical resection, specimens of gastric carcin-
omas and corresponding normal gastric tissue were ex-
cised by a pathologist and immediately snap frozen in
liquid nitrogen and stored at −80°C until usage. Tumour
samples were selectively taken from the macroscopically
identified tumour centre and the content of at least 70%
of tumour was verified by microscopy. Pathological re-
view, tumour staging, grading and typing were per-
formed according to the principles outlined by the
WHO [38] and the UICC [39]. Clinico-pathological pa-
rameters such as age, sex, primary site of disease,
Helicobacter pylori infection, lymphatic vessel invasion
and blood vessel invasion were recorded. Ethics Com-
mittee of the Medical Faculty, University Duesseldorf ap-
proved the study protocol (Number 3821).
RNA isolation
Total RNA of tissue specimen were isolated by per-
forming the acid guanidium thiocyanate phenol chloro-
form extraction with minor modifications as described
previously [40]. The quality of total RNA was confirmed
by integrity of the 28S and 18S ribosomal RNA in
ethidium-bromide stained agarose gels.
Reverse transcription and Semi-quantitative Polymerase
chain reaction
Reverse transcriptase reaction was performed in a final
volume of 20 μl using 2 μg total RNA and a final con-
centration of 5 mM MgCl2, 1 X reverse transcription
buffer, 1 mM each dNTP, 20 U recombinant RNase in-
hibitor RNasin, 15 U AMV reverse trancriptase as well
as 0.5 μg oligo(dT) primer (all Promega, Heidelberg,
Germany). The samples were incubated at 42°C for 1
hour with a final denaturation at 94°C for 15 min.
The amplification of the TRAIL splice variants was
performed on the LightCycler System (Roche Diagnos-
tics, Mannheim, Germany) using the Platinum SYBR
Green qPCR Super Mix-UDG kit (Invitrogen, Karlsruhe,
Germany). Therefore, 4 μl of synthesized cDNA was
amplified in a total volume of 20 μl containing 10 μl
Platinum SYBR Green qPCR Super Mix-UDG which in-
cluded the Taq DNA polymerase, SYBR Green I
Table 1 Distribution of tumour staging and typing of the
41 gastric carcinomas
pTNM stage UICC stage No. of patients
pT1 4
N0M0 I A 3
N1M0 I B 1
pT2 28
N0M0 I B 7
N1M0 II 13
N2M0 III A 5
N3M0 IV 3
pT3 8
N1M0 III A 3
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glycosylase (UDG), 1 μl BSA and 10 pmol of each TRAIL-α
specific primer (forward primer, GTC AGC TCG TTA
GAA AGA TGA T and reverse primer, GCT CAG GAA
TGA ATG CCC AC), TRAIL-β specific primer (forward
primer, ATG GCT ATG ATG GAG GTC CA and reverse
primer, GCT TTT CTT TCTAAC GAG CTG A); TRAIL-
γ specific primer (forward primer, ATG GCT ATG ATG
GAG GTC CA and reverse primer, GCT TTT CTG CTT
CAG CTC GT). In addition, the housekeeping gene
GAPDH was amplified using specific primers (forward pri-
mer, ACG GAT TTG GTC GTA TTG GGC G and reverse
primer, CTC CTG GAA GAT GGT GAT GG).
PCR assays were composed of an initial denaturation at
95°C for 5 min, followed by 50 cycles of 1 s denaturation
at 95°C, 20 s annealing at 64°C, extension at 72°C for 20 snon-neoplastic
Figure 1 Expression levels of TRAIL splice variants. Relative (GAPDH-no
and corresponding neoplastic gastric tissue specimen (N = 41). P-values weat a temperature transition rate of 20°C/s and a final ex-
tension at 72°C for 5 min. In every PCR the hot start was
performed to prevent the formation of unspecific products
and primer dimers. In addition to the melting curve ana-
lysis, specificity of the PCR was controlled by agarose gel
electrophoresis and products were sequenced with gene
specific oligonucleotides.
Quantification of TRAIL variants
The amount of TRAIL-α, TRAIL-β and TRAIL-γ tran-
scripts was calculated semi-quantitatively in relation to
the amount of the amplified housekeeping gene GAPDH
serving as external standard. For the relative quantifica-
tion, GAPDH specific PCR on cDNA standards compris-
ing a fivefold dilution series on cDNA synthesized from
HeLa cells was performed and used to create a standard
curve by plotting the crossing point (CP) values against
the dilution factor. Every dilution was run at least in du-
plicate. TRAIL-α, TRAIL-β, TRAIL-γ and GAPDH ex-
pression levels were normalised to the standard curve by
GAPDH expression levels obtained from these cDNA
standards which were amplified along the samples in
every run. The number of gene copies was calculated by
the LightCycler Software Version 3.5.3 according to the
second derivative maximum method.
Statistical analysis
GAPDH expression values for each sample were used to
normalise the respective amplification values of TRAIL
transcript and to calculate the ratios of relative mRNA
levels. Statistical analysis was performed using SPSS
12.01 statistical software package (SPSS Inc., Chicago,
IL, USA) or Graph Pad Prism 5 (GraphPad Software,
Inc., La Jolla, CA, USA). To determine the differences of
expression levels between the TRAIL splice variants in
normal or neoplastic transformed gastric tissue statistical
analyses were performed by using the Wilcoxon test.neoplastic
rmalized) mRNA levels of the different TRAIL variants in non-neoplastic
re calculated by the Wilcoxon-test; sv = splice variant.
Table 2 Correlation between expression levels of TRAIL









Stage (UICC) 24 0.682 0.588 0.721
I + II 17
III + IV
Histological gradea
G2 9 0.625 0.582 0.494
G3 31
Histological type




Positive 23 0.948 0.509 0.895
Negative 18
Blood vessel invasion
Positive 8 0.349 0.633 0.681
Negative 33
Helicobacter pylori infection
Positive 13 0.234 0.127 0.071
Negative 28
Sex
female 14 0.945 0.290 0.858
male 27
Age
< 64 Jahre 19 0.764 0.140 0.969
≥ 64 Jahre 22
aG1 (n=0) and G4 (n=1) not included due to the low case number.
bNot included in statistical analysis due to the low case number.
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variants according to clinico-pathological parameters
and between gastric carcinomas and normal gastric tis-
sues were analyzed using the Mann–Whitney–U–test.
One-way ANOVA and Bonferroni's Multiple Compari-
son test was performed to compare expression levels of
TRAIL splice variants with the primary site of gastric
cancer. A two-tailed p-value less than 0.05 was consid-
ered to indicate statistical significance.
For survival analyses the median expression level was
calculated and patients were categorized into two groups
(≥ median and < median). Life table curves were estimated
using the Kaplan-Meier analysis and the differences in sur-
vival were compared using the log-rank-test. A p-value less
than 0.05 indicated statistical significance. Multiple pro-
portional hazard Cox regression analysis was performed to
investigate the prognostic value of TRAIL splice variants
and clinico-pathological variables. The AIC (Akaike Infor-
mation Criteria) was used for model selection.
Results
TRAIL splice variants are expressed in neoplastic
and non-neoplastic gastric tissues
In this study we included patients that had undergone sub-
total or total gastrectomy because of gastric carcinomas
with UICC stages I-IV irrespectively of the tumour grading,
histological type, margins of resection, age, sex or tumour
localisation. Thus, we enrolled forty-one patients in this
study comprising 27 male and 14 female patients with a
median age of 64 ± 10.9 years (range 40–80 years). Samples
included gastric carcinomas classified as UICC stage I (n =
11), stage II (n = 13), stage III (n = 9) and stage IV (n = 8)
(Table 1). In seven patients margins of resection were
tumour positive as diagnosed by histology and therefore
being classified as R1 resection. Four patients showed at
the time of diagnosis already distant metastases.
Irrespective of the histological type, grade and stage of the
tumour, TRAIL-α TRAIL-β and TRAIL-γ could be detected
in all gastric carcinoma specimens and corresponding nor-
mal gastric tissue (Additional file 1: Figure S1). Specificity of
amplification was revealed by gel electrophoresis which
showed only a single amplification product (Additional file 1:
Figure S1) as well as by melting curve analysis (Additional
file 2: Figure S2). Whereas expression levels of the distinct
TRAIL variants showed only minor differences in normal
gastric tissues, TRAIL-α was the predominant transcript in
gastric carcinomas (p < 0.001) (Figure 1).
Correlations between the expression levels of TRAIL
splice variants and clinico-pathological parameters
To further evaluate whether expression patterns of the
different TRAIL variants might correlate with histo-
pathological variables such as tumour staging, grading,
typing, blood vessel invasion, lymphatic vessel invasionor Helicobacter pylori infection and other clinical param-
eters we performed the Mann–Whitney–U–test for non-
parametric data or one-way ANOVA and Bonferroni's
Multiple Comparison test to compare TRAIL expression
with tumour location. As summarized in Table 2, this
analysis did not provide any statistically significant cor-
relation between the investigated clinico-pathological
variables and the expression levels of wild type TRAIL-α
or the alternative splice variants TRAIL-β and TRAIL-γ.
TRAIL-β is downregulated in gastric carcinomas
Recently, exclusively the expression of TRAIL without
referring to its alternative splice variants has been
Figure 2 Expression of TRAIL-β is downregulated in gastric
carcinomas. Paired samples (N = 41) of non-neoplastic and
neoplastic gastric tissue where compared for expression levels of
TRAIL-α, -β and -γ. Two-tailed P-values were calculated by
the Mann–Whitney–U–test.
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Therefore, we analyzed the expression of the different
TRAIL splice variants by comparing matched neoplastic
and non-neoplastic tissue samples. Whereas the expres-
sion levels of TRAIL-α and -γ showed no significant dif-
ference when comparing gastric carcinomas with the
corresponding normal gastric tissue, TRAIL-β expres-
sion was significantly decreased in gastric carcinomas
(p = 0.001) (Figure 2).
Previously we reported that TRAIL-β and TRAIL-γ
are characterized by the loss of their proapoptotic func-
tion. Thus, a reduced production of the non-proapoptotic
isoforms by alternative splicing might result in an accu-
mulation of proapoptotic TRAIL-α mRNAs. Therefore,
we compared the mRNA expression levels of proapoptotic
TRAIL-α with those of non-proapoptotic TRAIL-β and -γ
in non-neoplastic as well as neoplastic tissues by calculat-
ing the ratio between mRNA levels of proapoptotic
TRAIL-α on one site and non-proapoptotic TRAIL-β plus
TRAIL-γ on the other site. Interestingly, this ratio revealed
a significant 2-fold increase of proapoptotic TRAIL-α in



























Figure 3 Ratio of mRNA levels between proapoptotic and non-
proapoptotic TRAIL isoforms. A significant increase for proapototic
TRAIL-α becomes evident in gastric carcinomas (N = 41) when
comparing the proapoptotic TRAIL-α with the non-proapoptotic
TRAIL-β and -γ isoforms.
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Figure 4 Prognostic impact of TRAIL splice variants. Kaplan-
Meier survival curves for TRAIL-α (A), TRAIL-β (B) and TRAIL-γ
(C) calculated from 33 patients with gastric carcinomas. Expression
of the non-proapoptotic TRAIL-γ variant was significantly associated
with a higher survival.
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In order to determine a prognostic value of mRNA
expression levels of TRAIL splice variants in gastric
carcinomas we estimated survival curves according
to Kaplan-Meier. To eliminate any bias on survival
analyses, eight patients were excluded from survival
analyses because of distant metastases (n = 4) and/or
non-tumour free resection margins (n = 7). The median
postoperative follow up of the remaining patients
(n =33) was 24 ± 51 months (range 1 – 148 months).
Whereas no statistical difference in survival could be
observed for the expression levels of TRAIL-α, and -β
(Figure 4A and B), high expression of non-proapoptotic
TRAIL-γ variant (≥ median 0.088) was significantly
(p = 0.02) associated with a better survival (TRAIL-γ
high vs. TRAIL-γ low: 6.1 vs. 1.2 years) (Figure 4C).
To provide better estimates of survival probabilities we
explored the impact of several variables on survival
using two Cox regression models. Thus, the model with
all possible interactions (model 1) such as the level of
expression of TRAIL-α, -β or -γ (high vs. low), lymphatic
vessel invasion, blood vessel invasion, histological type,
age, lymph node metastases, UICC stage and sex showed
an AIC value that was comparable to the AIC value of
the best model (model 2) (Table 3). In addition, as the
analysis of variance (ANOVA) revealed, interactions
among these variables were not statistically significant
(p = 0.51). We conclude empirically that the three vari-
ables: expression level of TRAIL-γ, age, and UICC stage
were independent prognostic factors.
Discussion
In this study, we analyzed the expression levels and
prognostic value of TRAIL splice variants in gastric car-
cinomas and compared the expression of these variants
in neoplastic tissues with the mRNA levels in corre-
sponding normal gastric tissues. In contrast to the work
by Koyama et al. [37] that reported a TRAIL protein ex-
pression in 55.6 % of the cells from primary gastric car-
cinomas and 53.7 % of the cells from metastatic gastric
carcinomas, respectively, we were able to detect TRAIL
in all gastric carcinoma samples on mRNA levels. This
difference might be explained by the use of the more
sensitive PCR method in our study. However, our study
demonstrates for the first time the expression of the pre-
viously identified TRAIL isoforms (i.e. TRAIL-β and -γ)
on mRNA levels in neoplastic and non-neoplastic gastric
tissue specimens.
Recently, TRAIL has attracted a lot of attention as
TNF-superfamily member because it is capable to trigger
apoptosis in neoplastic transformed cells, implicating its
potential as promising agent in targeted therapies
against cancer [3-9]. Although in some cases the com-
bination with chemotherapeutic agents is necessary toovercome TRAIL-resistance, first clinical trials show
antitumour activity only with mild side effects [9]. Aside
of its antitumor effects, TRAIL can activate via NF-кB
signaling pathways that promote survival by activation
of protein kinase B/Akt and MAP-Kinases [10,23-27].
However, the diversity in controlling TRAIL actions has
been extended by the molecular cloning of TRAIL-β and -γ
Table 3 Multivariate survival analysis after best model selection by the AIC
Model 1 Model 2
Variable HR 95% CI p-value HR 95% CI p-value
TRAIL-α 1.353e-01 1.074e-11 – 1.705e+09
TRAIL-β 1.934e+01 2.811e-23 –1.33331e+25
TRAIL-γ 1.682e-07 8.462e-14 – 3.343e-01 * 2.595e-07 5.902e-12 – 0.01141 **
Histological type 2.183e+00 4.643e-01 – 1.026e+01
Lymph node Metasasis 2.637e+00 3.606e-01 – 1.928e+01
UICC 9.464e+00 1.609e+00 – 5.568e+01 * 1.757e+01 4.524e+00 – 68.2543 ***
Age 1.133e+00 1.048e+00 – 1.225e+00 *** 1.119e+00 1.048e+00 – 1.19422 ***
Sex 1.111e+00 3.825e-01 – 3.225e+00
Rsquare 0.607 0.584
AIC 104.3138 100.2167
Significance codes: * indicates a p-value < 0.05, *** < 0.01 and *** < 0.001.
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tion of their N-terminal binding domain that consequently
results in a loss of function when overexpressed in mam-
malian cells [35]. Thus, these alternative splice variants may
be involved in the fine-tuning of TRAIL actions by simply
influencing the translation of the classical apoptosis indu-
cing TRAIL-α variant. In this context, alternative splicing
of pre-mRNA was found to play a functionally important
role as regulatory mechanism for apoptosis by processing
distinct mRNAs from a pre-mRNA that in turn results in
the translation of a pool of protein isoforms exhibiting
often antagonistic biological properties [33].
Herein, we show that TRAIL-α and its alternatively
spliced non-apoptotic isoforms TRAIL-β and -γ were
detectable on mRNA levels in matched pairs of normal
and neoplastic gastric carcinoma tissue specimens from
patients that underwent surgery because of gastric car-
cinoma. Moreover, these TRAIL-variants were expressed
in all histological types of gastric carcinoma, irrespective
of tumour grading and staging. Interestingly, proapoptotic
TRAIL-α exhibited the highest expression among the
TRAIL variants in neoplastic tissues, but not in normal
tissue specimens. In addition, the comparison between
normal and tumour tissue illustrated a significant decrease
of TRAIL-β mRNA levels in gastric carcinomas. A first
clue for a functional role of this tumour specific
downregulation became evident when comparing the ex-
pression levels of the proapoptotic TRAIL-variant with the
non-proapototic isoforms (TARIL-β and -γ), showing a
tumour specific increase of proapoptotic TRAIL-α. Thus,
the tumour specific downregulation of the TRAIL-β
mRNA might affect the TRAIL-α functions by a regulation
on mRNA levels. Since all TRAIL variants originate from
a common pool of a precursor RNA, the process of alter-
native splicing could permit an increase of proapoptotic
TRAIL-α mRNA if for example the spliceosome catalyzes
less RNAs with excluded exons such as TRAIL-β andTRAIL-γ transcripts. As a consequence, this could result
in an increase of translated TRAIL-α protein which could
support tumour growth by two ways. First, a TRAIL-
induced activation of NF-кB could mediate the transcrip-
tion of antiapoptotic targets such as XIAP and cFLIP,
protecting the tumour from proapoptotic stimuli and per-
mitting proliferation and metastasis. In this context, it has
been demonstrated that TRAIL supported the conversion
into a highly metastatic phenotype in pancreatic carcin-
omas by the induction of proinflammatory cytokines [29].
On the other hand, as suggested by others, the over-
expression of ligands of the TNF-family such as FasL and
TRAIL may be associated with immunological advantages
for tumour cells by counterattacking tumour infiltrating
cytotoxic lymphocytes [41-43]. In this context, a decrease
in the processing of non-proapoptotic TRAIL variants (i.e.
TRAIL-β and TRAIL-γ) as we observed in gastric carcin-
omas could permit the increase of translated TRAIL-α
which in turn could induce programmed cell death in
tumour infiltrating immune cells and thus promoting the
immune escape and tumour surveillance of gastric carcin-
omas. Since a decrease of synthesized TRAIL-γ transcripts
could permit an increase of transcribed and finally trans-
lated proapoptotic TRAIL-α, this could also explain our
observation that downregulation of TRAIL-γ was associ-
ated with a worse prognosis. Thus, we hypothesize that
the biological property of non-proapoptotic TRAIL splice
variants has to be more likely interpreted as result of com-
peting for translation with proapoptotic TRAIL-α.
Conclusion
Taken together, our present study provides first evidence
on the in vivo expression of TRAIL-splice variants in
gastric carcinomas. The tumour-specific downregulation
of TRAIL-β was associated with an increase of the
proapoptotic TRAIL-α isoform in neoplastic tissues
when compared to corresponding non-neoplastic tissue
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TRAIL-γ as an independent prognostic marker. These
data support the hypothesis that alternative splicing of
TRAIL may play a crucial role in the tumour biology of
gastric carcinomas.
Additional file
Additional file 1: Figure S1. Expression of TRAIL variants. RT-PCR
analyses of TRAIL splice variants in gastric carcinoma (A-C) and normal
gastric tissue (D-F) specimen by Real-Time-PCR (LightCycler) technology.
SYBR Green I mediated fluorescence (y-axis) upon amplification was
measured once per cycle (x-axis). TRAIL-α could be detected at cycles
24–28, whereas TRAIL-β and TRAIL-γ were detectable at cycles 28–32. The
specificity of amplification products by agarose gel electrophoresis is
shown in the upper framed box.
Additional file 2: Figure S2. Melting curve analyses of amplified PCR
products. Melting curve analyses from exemplary PCR experiments of
A) TRAIL-α, B) TRAIL-β and C) TRAIL-γ from exemplary PCR experiments
demonstrated that only one specific product was amplified.
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